β-d-Glucan and Candida albicans germ tube antibody in ICU patients with invasive candidiasis

Intensive Care Medicine

Volumn 41, Issue 8, 2015, Pages 1424-1432

  Martín Mazuelos, Estrella ^a   Loza, Ana ^a   Castro, Carmen ^a   Macías, Desirée ^a   Zakariya, Ismail ^a   Saavedra, Pedro ^b   Ruiz Santana, Sergio ^c   Marín, Elena ^a   León, Cristóbal ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^c HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

Author keywords

(1 3) D glucan; Antifungal treatment; Biomarker kinetics; Candida albicans germ tube antibody; Candida spp. colonization; Enteral nutrition; Invasive candidiasis

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN B LIPID COMPLEX; BETA GLUCAN; CANDIDA ALBICANS GERM TUBE ANTIBODY; ECHINOCANDIN; FUNGUS ANTIBODY; PIPERACILLIN PLUS TAZOBACTAM; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADULT; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL COLONIZATION; BLOODSTREAM INFECTION; CANDIDA ALBICANS; COHORT ANALYSIS; CONTROLLED STUDY; CRITICALLY ILL PATIENT; ENTERIC FEEDING; FEMALE; GRAM POSITIVE INFECTION; HUMAN; INVASIVE CANDIDIASIS; MAJOR CLINICAL STUDY; MALE; PATIENT HISTORY OF SURGERY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; AGED; BLOOD; CANDIDIASIS, INVASIVE; IMMUNOLOGY; INTENSIVE CARE UNIT; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SPAIN;

ADULT; AGED; ANTIBODIES, FUNGAL; BETA-GLUCANS; BIOMARKERS; CANDIDA ALBICANS; CANDIDIASIS, INVASIVE; COHORT STUDIES; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SPAIN;

EID: 84937816585     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-015-3922-y     Document Type: Article

References (38)

1. León C, Ostrosky-Zeichner L, Schuster M (2014) What’s new in the clinical and diagnostic management of invasive candidiasis in critically ill patients. Intensive Care Med 40:808–819
2. Lortholary O, Renaudat C, Sitbon K, Madec Y, Denoeud-Ndam L, Wolff L, Fontanet A, Bretagne S, Dromer F, The French Mycosis Study Group (2014) Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002–2010). Intensive Care Med 40:1303–1312. doi:10.1007/s00134-014-3408-3
3. Colombo AL, Guimaraes T, Sukienik T, Pasqualotto AC, Andreotti R, Queiroz-Telles F, Nouer SA, Nucci M (2014) Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. Intensive Care Med 40:1489–1498. doi:10.1007/s00134-014-3400-y
4. Maubon D, Garnaud C, Calandra T, Sanglard D, Cornet M (2014) Resistance of Candida spp. to antifungal drugs in the ICU: where are we now? Intensive Care Med 40:1241–1255. doi:10.1007/s00134-014-3404-7
5. Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas MP (2011) (1→3)-β-d-Glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis 52:750–770
6. Mohr JF, Sims C, Paetznick V, Rodriguez J, Finkelman MA, Rex JH, Ostrosky-Zeichner L (2011) A prospective survey of (1,3)-β-d-glucan and its relationship to invasive candidiasis in the surgical ICU setting. J Clin Microbiol 49:58–61
7. Posteraro B, De Pascale G, Tumbarello M, Torelli R, Pennisi MA, Bello G, Maviglia R, Fadda G, Sanguinetti M, Antonelli M (2011) Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1,3)-β-d-glucan assay, Candida score, and colonization index. Crit Care 15:R249
8. Del Bono V, Delfino E, Furfaro E, Mikulska M, Nicco E, Bruzzi P, Mularoni A, Bassetti M, Viscoli C (2011) Clinical performance of the (1,3)-β-d-glucan assay in early diagnosis of nosocomial Candida bloodstream infections. Clin Vaccine Immunol 18:2113–2117
9. Tissot F, Lamoth F, Hauser PM, Orasch C, Fluckiger U, Siegemund M, Zimmerli S, Calandra T, Bille J, Eggimann P, Marchetti O (2013) Beta-glucan antigenemia anticipates diagnosis of blood culture negative intra-abdominal candidiasis. Am J Respir Crit Care Med 188:1100–1109
10. Leon C, Ruiz-Santana S, Saavedra P, Castro C, Ubeda A, Loza A, Martin-Mazuelos E, Blanco A, Jerez V, Balluss J, Alvarez-Rocha L, Utande-Vazquez A, Fariñas O (2012) Value of (1→3) β-d-glucan and Candida albicans germ tube antibody for discriminating between Candida colonization and invasive candidiasis in patients with severe abdominal conditions. Intensive Care Med 38:1315–1325
11. Racil Z, Kocmanova I, Lengerova M, Weinbergerova B, Buresova L, Toskova M, Winterova J, Timilsina S, Rodriguez I, Mayer J (2010) Difficulties in using (1,3)-β-d-glucan as the screening test for the early diagnosis of invasive fungal infections in patients with haematological malignancies—high frequency of false-positive results and their analysis. J Med Microbiol 59:1016–1022
12. Pickering JW, Sant HW, Bowles CAP, Roberts WL, Woods GL (2005) Evaluation of a (1,3)-β-d-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 43:5957–5962
13. Theel ES, Doern CD (2013) (1,3)-β-d-Glucan testing is important for diagnosis of invasive fungal. J Med Microbiol 57:287–295
14. Martinez M, Muñoz P, Guinea J, Martos C, Valerio M, Alonso R, Escribano P, Bouza E (2014) Potential role of Candida albicans germ tube antibody (CAGTA) in the diagnosis of deep-seated candidemia. Med Mycol 52:270–275
15. Zaragoza R, Peman J, Quindos G, Iruretagoyena JR, Cuetara MS, Ramırez P, Gomez MD, Camarena JJ, Viudes A, Ponton J (2009) Clinical significance of the detection of Candida albicans germ tube-specific antibodies in critically ill patients. Clin Microbiol Infect 15:592–595
16. Pemán J, Zaragoza R, Quindós R, Alkorta M, Cuétara MS, Camarena JJ, Ramírez P, Giménez MJ, Martín Mazuelos E, Linares Sicilia MJ, Pontón J (2011) Clinical factors associated with a Candida albicans germ tube antibody positive test in intensive care unit patients. BMC Infect Dis 11:60
17. Loza A, Castro C, Zakariya I, Macias D, Saavedra P, Ruiz-Santana S, Martin-Mazuelos E, Leon C (2014) Candida infection in non-neutropenic ICU patients: value of (1,3)-β-d-glucan and Candida albicans germ tube antibody. Intensive Care Med 40(Suppl 1):S130 (Abstract 0455)
18. Clancy CL, Nguyen MH (2014) Undiagnosed invasive candidiasis: incorporating non-culture diagnostics into rational prophylactic and preemptive antifungal strategies. Expert Rev Anti Infect Ther 12:731–734. doi:10.1586/14787210.2014.919853
19. León C, Ruiz-Santana S, Saavedra P, Galván B, Blanco A, Castro C, Balasini C, Utande-Vázquez A, González de Molina FJ, Blasco-Navalproto MA, López MJ, Charles PE, Martín E, Hernández-Viera MA (2009) Usefulness of the Candida score for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 37:1624–1633
20. Eggimann P, Pittet D (2014) Candida colonization index and subsequent infection in critically ill patients: 20 years after. Intensive Care Med 40:1429–1448
21. Bassetti M, Marchetti M, Chakrabarti A, Colizza S, Garnacho-Montero J, Kett DH, Munoz P, Francesco Cristini F, Andoniadou A et al (2013) A research agenda on the management of intraabdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med 39:2092–2106
22. Clancy CJ, Nguyen MH (2013) Finding of the missing 50% of invasive candidiasis: how non-culture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis 56:1284–1292
23. Ellis M, Al-Ramadi B, Finkelman M, Hedstrom U, Kristensen J, Ali-Zadeh H, Klingspor L (2008) Assessment of the clinical utility of serial beta-d-glucan concentrations in patients with persistent neutropenic fever. J Med Microbiol 57:287–295
24. Hanson KE, Pfeiffer CD, Lease ED, Balch AH, Zaas AK, Perfect JR, Alexander BD (2012) (1,3)-β-d-Glucan surveillance with preemptive anidulafungin for invasive candidiasisin intensive care unit patients: a randomized pilot study. PLoS One 7:e42282
25. Held J, Wagner D (2010) (1,3)-β-d-Glucan kinetics for the assessment of treatment response in Pneumocystis jirovecii pneumonia. Clin Microbiol Infect 17:1118–1822
26. Sims CR, Jaijakul S, Mohr J, Rodriguez J, Finkelman M, Ostrosky-Zeichner L (2012) Correlation of clinical outcomes with beta-glucan levels in patients with invasive candidiasis. J Clin Microbiol 50:2104–2106
27. Jaijakul S, Vazquez JA, Swanson RN, Ostrosky-Zeichner L (2012) (1,3)-β-d-Glucan as a prognostic marker of treatment response in invasive candidiasis. Clin Infect Dis 55:521–526
28. Koo S, Baden LR, Marty FM (2012) Post-diagnostic kinetics of the (1,3)-β-d-glucan assay in invasive aspergillosis, invasive candidiasis and Pneumocystis jirovecii pneumonia. Clin Microbiol Infect 18:E122–E127
29. Mikulska M, Furfaro E, Del Bono V, Gualandi F, Van Lint MT, Miletich F, Bacigalupo A, Viscoli C (2011) Persistence of a positive (1,3)-β-d-glucan test after clearance of candidemia in hematopoietic stem cell transplant recipients. Clin Vaccine Immunol 18:518–519
30. Sulahian A, PorcherR Bergeron A, Touratier S, Raffoux E, Menotti J, DerouinF Ribaud P (2014) Use and limits of (1,3)-β-d-glucan (Fungitell), compared to galactomannan determination (Platelia Aspergillus), for diagnosis of invasive aspergillosis. J Clin Microbiol 52:2328–2333
31. Marty FM, Lowry CM, Lempitski SJ, Kubiak DW, Finkelman MA, Baden LR (2006) Reactivity of (1,3)-β-d-glucan assay with commonly used intravenous antimicrobials. Antimicrob Agents Chemother 50:3450–3453
32. Metan G, Agkus C, Buldu H, Koc AN (2010) The interaction between piperacillin/tazobactam and assays for Aspergillus galactomannan and 1,3-beta-d-glucan in patients without risk factors for invasive fungal infections. Infection 38:217–221
33. Albert O, Toubas D, Strady C, Cousson J, Delmas C, Vernert V, Villena I (2011) Reactivity of (1→3)-β-d-glucan assay in bacterial bloodstream infections. Eur J Clin Microbiol Infect Dis 30:1453–1460
34. Metan G, Agkus C, Koc AN, Elmaili F, Finkelman MA (2012) Does ampicillin-sulbactam cause false positive of (1,3)-β-d-glucan assay? A prospective evaluation of 15 patients without invasive fungal infections. Mycoses 55:366–371
35. Racil R, Kocmanova I, Toskova M, Winterova J, Timilsin S, Lengerova M, Mayer J (2013) Reactivity of the (1,3)-β-d-glucan assay during bacteraemia: limited evidence from a prospective study. Mycoses 56:101–104
36. Furfaro E, Mikulska M, Del Bono V, Guolo F, Minetto P, Gobbi M, Ghiso A, Bacigalupo A, Viscoli C (2014) Bloodstream infections are an improbable cause of positive serum (1,3)-β-d-glucan in hematology patients. Clin Vaccine Immunol 21:1357–1359
37. Spriet I, Desmet S, Willems L, Lagrou K (2011) No interference of the 1,3-β-d-glucan containing ImunixX with the 1,3-β-d-glucan serum test. Mycoses 54:e352–e353
38. Zaragoza R, Peman J, Quindos G, Iruretagoyena JR, Cuetara MS, Ramírez P, Gomez MD, Camarena JJ, Viudes A, Ponton J, on behalf of the Candida albicans Germ Tube Antibody Detection in Critically Ill Patients (CAGTAUCI) Study Group (2009) Kinetic patterns of Candida albicans germ tube antibody in critically ill patients: influence on mortality. Clin Vaccine Immunol 16:1527–1528